Reaction: Vaccination against RSV in pregnant women protects their babies, but increases the risk of preterm birth, according to a phase III clinical trial
The NEJM publishes the results of a phase III clinical trial conducted by GSK that had to be suspended due to a safety signal. The study shows that newborns of vaccinated mothers had a lower risk of experiencing severe events associated with the respiratory syncytial virus (RSV), but also a higher risk of being born prematurely.